Abstract: The present invention provides a novel anticariogenic agent without side effects so that anticariogenic effect can also be obtained in humans who are highly sensitive to oligosaccharides and sugar alcohols. Also, an agent for preventing periodontal disease or for treating periodontal disease which has an effect of preventing or treating periodontal disease and which does not have side effects is provided. The invention relates to an anticariogenic agent and an anticariogenic composition comprising a bifidobacterium, an agent and a composition for preventing periodontal disease comprising a bifidobacterium and an agent and a composition for treating periodontal disease comprising a bifidobacterium.

Abstract: The invention surprisingly found that Lactobacillus plantarum subsp. plantarum PS128 provides an advantageous effect in treatment or prevention of tic disorders and basal ganglia disorders. Accordingly, the invention provides a method of treating or preventing a movement disorder in a subject, comprising administering to a subject an effective amount of cells of a Lactobacillus plantarum subsp. plantarum PS128, which is deposited under DSMZ Accession No. DSM 28632.

Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.

Abstract: The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.

Abstract: Artificial cervical fluid is disclosed that contains a mucilaginous extract from the okra plant. The mucilaginous extract can be produced using a hot aqueous extractant or cold extraction process followed by separation of larger particles from the extract. The extract finds many uses, for example as a sperm storage medium, a sperm freezing medium, a sexual lubricant, an artificial insemination medium, and an in vitro fertilization medium.

Abstract: An extract of seeds of Emblica officinalis which has triterpenoids and hydroxycinnamic acids is provided. A blend of extracts of seeds of Emblica officinalis which includes an extract of seeds of Emblica officinalis having triterpenoids and hydroxycinnamic acids and an extract of seeds of Emblica officinalis having fatty acids, such as, alpha linolenic acid, linoleic acid and oleic acid is provided. Methods of preparing the extracts of seeds of Emblica officinalis and methods of preparing the blend of extracts of seeds of Emblica officinalis are provided. Methods of treatment administering the extracts of seeds of Emblica officinalis and methods of preparing the blend of extracts of seeds of Emblica officinalis are provided.

Abstract: Methods of manufacturing vegetable powders and/or vegetable compositions are described herein.

Abstract: The present invention relates to extracts, compounds isolated from Cakile arabica for use in the treatment of ulcer and to pharmaceutical compositions thereof.

Abstract: A preparation method of Gynostemma Pentaphyllus leaves extracts with increased amount of small molecular effective saponin and decreased benzopyrene includes the steps of drying fresh Gynostemma Pentaphyllus leaves after heating, treating the dried Gynostemma Pentaphyllus leaves with steam, adding water of 1 to 100-fold volume to the above Gynostemma Pentaphyllus leaves and then preparing a hot water extract by carrying out a hot water extraction at 100-180 V, 0.5-10 atm for 1-120 hours, adding C1-C4 lower alcohol of 1 to 100-fold volume to the residual remained after the hot water extraction and then preparing an alcohol extract of the residual from the hot water extract by carrying out an alcohol extraction at 50-100° C. for 1-4 hours, and mixing the hot water extract and the alcohol extract, and then filtering and concentrating the mixture.

Abstract: A fish feed includes carvacrol and/or salvia extract (provided that where the fish feed comprises carvacrol and not salvia extract the lipid content of the fish feed is at least 15 wt %). The salvia extract may be selected from extract of Salvia officinalis and extract of Salvia lavandulifolia. The carvacrol may be synthetic or may be extracted from Origanum vulgare.

Abstract: The invention discloses taste masking formulations for bitter natural compounds, selected from the extracts, fraction and pure phytochemicals produced in combination with a synthetic polymer or a natural polymer. The invention also relates to the novel process of producing the taste masking formulations. The invention also relates to taste masking formulations of Bacopa extracts with no bitter taste or negligible bitter taste in combination with synthetic polymers such as Eudragit or natural polymers such as Shellac.

Abstract: The present invention involves the application of Semen Ziziphi Spinosae oil in the preparation of drugs for treating medicinal insomnia. Semen Ziziphi Spinosae oil has a therapeutic effect on insomnia caused by ephedrine, prednisone and other drugs, and Semen Ziziphi Spinosae oil that is prepared within the pressing temperature of 80 to 100° C. has the best efficacy for treating medicinal insomnia.

Abstract: The present invention is directed to a therapeutic method of independent or adjuvant treatment of Parkinson's disease and Parkinson's syndrome, comprising administering to a subject in need a therapeutically effective amount of Chinese medicine composition, wherein the Chinese medicine composition comprises the extract of the mixture of Rhizoma Pinelliae, Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, Rhizoma Atractylodis, Rhizoma Alismatis, Pericarpium Citri Reticulatae, Massa Medicata Fermentata, Fructus Hordei Germinatus, Rhizoma Zingiberis, Cortex Phellodendri, rhizoma Gastrodiae, Radix Aconiti Lateralis Praeparata, Radix Angelicae Sinensis, and Radix Astragali.

Abstract: The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintainance of a healthy gut-mucosa and/or for the provision of an increased barrier function of the gut-mucosa.

Abstract: The present disclosure relates to a herbal oil formulation based on bark extract of Heterophragma roxburghii, that can be applied topically and can be used to for treating and curing various skin conditions and diseases, all types of wounds, and other therapeutic conditions associated with diminished blood flow in humans and animals. The disclosed topical herbal oil formulation provides an inexpensive alternative healing therapy for various therapeutic conditions such as, but not limited to, diabetic gangrene, dry gangrene, wet gangrene, athlete's foot, burn wounds, diabetic foot ulcer, bed sore, chronic open wounds, wounds caused by snake bite, and gangrene formed due to cellulitis.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

Abstract: The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating cellular neurodamage or neurotrauma to the peripheral or central nervous system using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.

Abstract: Provided is a nanoparticle associated with a plurality of oleylcysteineamide (OCA) molecules for a variety of therapeutic applications. At least a portion of the OCA molecules may be associated with at least one therapeutic agent or at least one non-active agent. Also provided is a drug delivery agent including at least one nanoparticle associated with a plurality of OCA molecules. At least a portion of the OCA molecules is associated with at least one therapeutic agent or at least one or non-active agent. Also provided is a method of delivering a drug to a subject. The method includes administering the drug delivery agent (associated with the drug) to the subject.

Abstract: The present disclosure provides, in some embodiments, compositions, kits, systems, and methods for reducing bacteria on a surface (e.g., a medical device) and preventing and/or treating a bacterial infection (e.g., urinary tract infection) in a subject using IdsD protein or a fragment thereof.

Abstract: Disclosed is a composition for use in the prevention or treatment of a subject suffering from a cancer in combination with radiotherapy, wherein the composition includes a conjugate, eventually associated with pharmaceutically acceptable carrier, the conjugate including i) the Shiga Toxin B subunit (STxB), a fragment or a derivative thereof; and ii) at least one epitope associated with the cancer.

Abstract: The present invention relates to a protein derived from lactic acid bacteria and a method for producing the same. The lactic acid bacteria-derived protein of the present invention is a purified protein isolated from lactic acid bacteria (Lactobacillus rhamnosus) having an excellent therapeutic effect against colorectal cancer. It has been demonstrated to have a remarkable effect against colorectal diseases, and thus is expected to be widely used as a natural protein therapeutic agent against colorectal diseases in the medical field.

Abstract: This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now® to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now® formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.

Abstract: The subject of the present invention is pharmaceutical composition containing active ingredients in the form of a peptide of the myelin basic protein, a peptide from the myelin protein and oligodendrocytes as well as a peptide of the proteolipid protein as well as the use of the composition in the manufacturing of a drug for topical administration in the treatment of the disease multiple sclerosis. The composition may be administered topically.

Abstract: The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocytes or their activity using such compounds. The compounds may include both antibodies as well as small molecules. The methods may involve administering the compounds to a patient with or at risk of developing fibrosis in a manner that inhibits at least one sialidase in the patient.

Abstract: Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.

Abstract: Neonatal NET-Inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.

Abstract: In some aspects, provided herein is a method of enhancing production of interleukin-17 (IL-17), interferon gamma (IFN-?), or both by a mammalian T cell, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of enhancing Th1 and/or Th17 responses by a mammalian T cell, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of enhancing production of interleukin-6 (IL-6), interleukin 1 beta (IL-1?), or both by a mammalian T cell or monocyte, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of decreasing suppressive activity of a T regulatory cell, e.g., a natural regulatory T (nTreg) cell, the method comprising contacting a Treg cell, e.g., an nTreg cell, with an inhibitor of C5L2.

Abstract: In an aspect of the present application, compositions and methods are provided for preventing bone loss and/or stimulating bone healing in a subject in need thereof. Compositions can comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of a zinc-finger CCHC domain-containing protein 6 (ZCCHC6) inhibitor. Methods can include administering a therapeutically effective amount of the ZCCHC6 inhibitor to the subject.

Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the prevention of EPI or pancreatitis resulting from surgical procedures.

Abstract: The present application discloses PEG modified variants of a bFGF-21 polypeptide, compositions containing a bFGF-21 polypeptide variant, and methods useful in treating and/or preventing ketosis that administer the variant or a composition containing said bFGF-21 variant.

Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non -agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.

Abstract: A method of treating a subject for acute nicotine withdrawal generally includes intranasally administering to the subject a dose of insulin effective to ameliorate at least one symptom or clinical sign of nicotine withdrawal. In some embodiments, the dose of insulin can be at least 45 IU and no more than 75 IU. In one particular embodiment, the dose can be 60 IU. In some embodiments, the dose can be an amount effective to restore at least a portion of a nicotine-withdrawal-associated decrease in saliva Cortisol level following a stress stimulus. In some embodiments, the dose can be an amount effective to decrease an urge to smoke a cigarette during cute withdrawal from nicotine.

Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.

Abstract: Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with ?2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with ?2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.

Abstract: The invention provides a blood substitute product comprising haemoglobin and a self-assembled microparticle having an acid having two or more acid groups and an organic base in a solvent. The particle is of micron scale. The microparticle may be obtained by contacting a bis-acid and organic base in a hydrophilic solvent, wherein the acid is insoluble or sparingly soluble in the hydrophilic solvent and the organic base is soluble in a hydrophilic solvent.

Abstract: The present invention relates to a use of earthworm protein. Particularly, the present invention provides a use of earthworm protein for preparing a pharmaceutical composition which can enhance the expression of an antioxidant gene in brain neurons or inhibit the effects of ?-amyloid protein (A?) and 1-methyl-4-phenylpyridinium (MPP+) on brain neurons. As such, the pharmaceutical composition comprising the earthworm protein has effects of reducing damage to brain neurons.

Abstract: Provided are CD4+ T-cell-based compositions and methods for treating hypertension.

Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis. Also, described are compositions and methods for preventing, treating or ameliorating an inflammation-mediated and/or complement-mediated disease or condition in a subject comprising administering to the subject a Fas inhibitor, its derivative, a pharmaceutically acceptable salt thereof, of a gene therapy encoding the Fas inhibitor in an amount effective to inhibit Fas signaling.

Abstract: The invention provides compositions and methods for treating human papillomavirus (HPV) infections using a targetable nuclease, which compositions and methods can be used to selectively target the HPV genome or selectively express the targetable nuclease within cells that infected by HPV. By selectively targeting cells infected by HPV, the HPV genome within infected cells, or both, the nuclease is able to cleave the HPV genome thereby inactivating it and rendering it inoperable, interfering with the virus's ability to propagate even where the virus is in a latent stage of infection. Since latent HPV can be cleaved and eradicated from the host cells, compositions and methods of the invention may be used to treat HPV infections and potentially prevent many of the adverse health consequences associated with the papillomavirus.

Abstract: The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.

Abstract: The present invention relates to treatment and prevention of cancer with glycosidase(s). In various aspects the invention relates to the treatment and management of cancer to prevent metastasis or recurrence, or to improve outcome and rate of successful treatment with conventional therapeutic regimens.

Abstract: The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.

Abstract: The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention be can easily store and distribute. AND it was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.

Abstract: A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of complex regional pain syndrome, or the likelihood of an individual to develop complex regional pain syndrome is disclosed.

Abstract: Methods for treating cancers, such as breast cancer or skin cancer, using an ACE or ARB, or a combination of celecoxib and olmesartan.

Abstract: The present invention describes use of spink6 gene and the encoded protein in the manufacture of an anti-tumor drug. spink6 gene has a nucleotide sequence designated as SEQ ID NO:1, and the protein encoded by spink6 gene has an amino acid sequence designated as SEQ ID NO:2. The protein encoded by spink6 gene and its derivatives can be used as potential drugs for treatment of human diseases caused by dysregulation of the cell cycle control, such as various malignant tumors, cell abnormal proliferation, and the like.